8 Weeks on Wegovy: What Clinical Evidence and Real Progress Look Like

Where the STEP 1 trial evidence places week eight

The STEP 1 trial recruited 1,961 adults with obesity or overweight and at least one weight-related condition, running for 68 weeks. At the end of that period, participants on 2.4mg semaglutide had lost an average of around 15% of their body weight, compared with about 2.4% on placebo. Week eight sits early in that arc. Participants were still in the dose-escalation phase: the Wegovy titration schedule moves from 0.25mg through 0.5mg and 1mg before reaching 1.7mg and then 2.4mg, with roughly four weeks at each level. So at the eight-week mark, the dose most people are reaching is 1mg, which is not yet the therapeutic maintenance dose.

That matters for expectations. The NHS medicines page for semaglutide is clear that it takes time for the full effect to establish. Individual responses at this stage range widely: some people notice a noticeably quieter appetite from the first few weeks; others feel little different until the higher doses kick in. Both patterns are consistent with the evidence.

Side effects most likely to peak around weeks six to eight

Gastrointestinal effects (nausea, loose stools, indigestion, occasional vomiting) are most common in the days after each dose increase. For a lot of people, week eight coincides with the 1mg step, which can bring a fresh wave of mild GI symptoms before the body settles again. The evidence from the STEP trials is that these effects are generally most pronounced during up-titration and taper off once a dose is stable. Persistent or severe stomach pain that radiates to the back is different in character and should prompt prompt medical attention, given the known association with acute pancreatitis flagged by the MHRA.

Fatigue, headache and dizziness are also reported, particularly in the first days after a step-up. Practical things that help: eating smaller portions more slowly, staying well hydrated, and not skipping meals entirely even when appetite is low. None of that is a substitute for talking to your prescriber if something feels wrong. Side effects can be reported directly to the MHRA via the Yellow Card scheme, which is open to patients as well as healthcare professionals.

Weight loss at eight weeks: what's realistic to expect

Trying to pin a precise number to week eight is genuinely difficult, and any service that gives one with confidence is overstating the evidence. What the trials do show is that meaningful weight loss tends to accelerate once patients reach and sustain the maintenance dose. In the early weeks, the change on the scales may feel modest (a few pounds for some, more for others) while the more visible appetite changes are often what people first notice.

If you started Wegovy wondering whether it was working for you, the honest answer at eight weeks is that you are likely still in the build-up phase. Comparing your own progress to what you read online is rarely useful; individual biology, starting weight, diet and activity level all pull the results in different directions. Our Wegovy treatment overview covers what the licensed evidence shows across the full programme.

For context on the financial side of long-term treatment, the Wegovy cost page sets out what private treatment typically involves and what a single transparent price from a regulated pharmacy should include.

What a prescriber should be checking at this stage

Eight weeks in, a responsible prescriber is not just confirming the next supply. They are looking at tolerability, actual weight change, any changes in medical history, and whether the dose increase is clinically appropriate. At nume, every repeat is clinically re-reviewed — not automatically approved because the last one was fine. A question our prescribers hear regularly at this stage is whether to slow the titration down, because someone is finding the side effects difficult. Slowing the schedule is a legitimate clinical choice; it does not mean the treatment isn't working.

If you are still learning about how semaglutide works, or thinking about what the first few weeks of treatment involve, our earlier progress pages cover the experience at two weeks and what week six typically looks like. Some people also find it useful to revisit the four-week point to sense-check how their own journey compares to the pattern. If you have questions for our clinical team, the contact page reaches us seven days a week.

Wegovy is a prescription-only medicine. If you are not yet in treatment and are wondering whether it might suit you, checking your eligibility through a free consultation is the right place to start, a GPhC-registered prescriber reads every submission the same day.